Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05529095
Other study ID # PRO00033518
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date September 1, 2022
Est. completion date March 1, 2023

Study information

Verified date September 2022
Source The Methodist Hospital Research Institute
Contact William Ondo, MD
Phone 713-363-8184
Email wondo@houstonmethodist.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses.


Description:

This is an open label, with a short placebo-controlled portion trial using sublingual apomorphine (Kynmobi) in RLS patients inadequately treated with standard therapy, defined by an IRLS > 15 and report of breakthrough symptoms. At the initial visit, subjects will undergo all baseline and exploratory assessments and be given their first drug dose of 10 mg. They will be monitored for 60 minutes after dose. Subjects orthostatic blood pressure will be taken before ingestion, then 10, 20, 30, and 45 minutes after ingestion. Over the next 4 weeks, subjects will titrate Kynmobi to find optimal dose. Subjects will be instructed to take at least 2 doses before determining if further titration is needed. At week 4, subjects will return for exploratory assessments. Subjects will be given a randomized study drug packet containing 2 placebos and 2 drug doses. Subjects will be told that 0-4 doses may be placebo or drug. Subjects will have 4 weeks to complete randomization doses. It is anticipated subjects will complete randomization sooner, so they will be given 23 doses of study drug (1 dose per 24 hours for 23 extra days until next visit). At week 8, subjects will return for exploratory assessments and be given an additional 74 dosed strips. They will return at week 16 for a final visit and undergo exploratory assessments, followed by a safety call two weeks later. From weeks 0-8, subjects are able to continue their scheduled RLS medications. From weeks 8-16, subjects may make changes to their RLS medications as mutually agreed upon with investigator. Several questionnaire assessments will be conducted throughout the study to monitor subjects. Subjects will complete the International RLS Rating Scale (IRLS), Restless Legs Syndrome - 6 Scale (RLS - 6), RLS Quality of Life Questionnaire (RLSQoL), RLS Augmentation Scale, Fatigue Severity Scale (FSS), Hamilton Depression Scale (HDS), Clinical Global Impressions (CGI), and Clinical Global Impressions-Change (CGI-C).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 16
Est. completion date March 1, 2023
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - Idiopathic RLS diagnosed by standard criteria, with an IRLS > 15 while taking at least 1 RLS medication - Stable RLS medications for at least 2 weeks prior to study entry Exclusion Criteria: - Concurrent untreated sleep disorders, not felt to be able stable - Subjects with any significant, unstable cardiovascular, liver, lung, renal. psychiatric, or neurological diseases (not including RLS) - Any medical or psychiatric comorbidity that, in the opinion of the investigator, would make study compliance difficult to achieve - Intravenous iron within 4 weeks of study entry - Breast feeding or pregnancy determined by urine pregnancy test in subjects where pregnancy is a possibility (pre-menopausal, sexually active women) - Subjects with previous allergic reaction to apomorphine or sulfate sensitivity - Subjects currently taking 5HT3 antagonists

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Apomorphine Sublingual Film
Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
Placebo
Placebo (sugar pill)

Locations

Country Name City State
United States Houston Methodist Hospital Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
William Ondo, MD Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analogue Scale of Improvement Subjects will assess how they feel 30 minutes after taking four doses of drug or placebo. Weeks 4 - 8
Secondary International RLS Rating Scale (IRLS) This is a subjective scale to measure the severity of RLS within the past week. Baseline, 4 weeks, 8 weeks, and 16 weeks
Secondary The Restless Legs Syndrome - 6 Scale (RLS-6) This scale measures the severity of daytime versus nighttime RLS symptoms. Baseline, 4 weeks, 8 weeks, and 16 weeks
Secondary Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL) This scale assess the quality of life in RLS patients. Baseline, 4 weeks, 8 weeks, and 16 weeks
Secondary Hamilton Depression Scale (HDS) This scale assess symptoms of depression. Baseline, 4 weeks, 8 weeks, and 16 weeks
Secondary Epworth Sleepiness Scale (ESS) This is a subjective scale that measures a patient's sleepiness. Baseline, 4 weeks, 8 weeks, and 16 weeks
Secondary Clinical Global Impressions - Change This scale assess how much a patients illness has improved or worsened when compared to a baseline state from the beginning of the intervention. 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, 12 weeks, 16 weeks, and 18-20 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Completed NCT01455012 - Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Phase 4
Terminated NCT01192503 - Safety and Efficacy of Rasagiline in Restless Legs Syndrome Phase 2/Phase 3
Completed NCT00721279 - Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome N/A
Completed NCT00530530 - ASP8825 - Study in Patients With Restless Legs Syndrome Phase 2
Completed NCT00375284 - A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS Phase 4
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00479531 - Sequential Compression Devices for Treatment of Restless Legs Syndrome Phase 3
Recruiting NCT05581576 - Pitolisant in Refractory Restless Legs Syndrome Phase 4
Active, not recruiting NCT03218969 - Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist Phase 1/Phase 2
Recruiting NCT04144790 - Impact of Iron Supplementation Treatment on Brain Iron Concentrations
Completed NCT05787080 - Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS) N/A
Recruiting NCT05044520 - Clinical Features Associated With Restless Legs Syndrome.
Withdrawn NCT03849001 - Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS N/A
Completed NCT03076541 - Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements. N/A
Recruiting NCT04145674 - A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo Phase 2
Completed NCT02532608 - Infra-slow Oscillations During Sleep N/A
Completed NCT01528462 - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed NCT00748098 - Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance Phase 3
Completed NCT00373542 - 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome Phase 4